Meeting
2013 ASCO Annual Meeting
The ENCHANT-1 trial (NCT01677455): An open label multicenter phase II proof of concept study evaluating first-line ganetespib monotherapy in women with metastatic HER2-positive or triple-negative breast cancer (TNBC).
Authors
Ahmad Awada
Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium
Ahmad Awada , Angel Augusto Rodriguez , Anthony Kong , John Kalil Erban , Javier Cortes , Max S. Mano , Edith A. Perez , Iman El Hariry , Vojislav M. Vukovic , Florentina Teofilovici , Ilker Yalcin , Robert Bradley , David A. Cameron
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer - Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT01677455
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS1136)
DOI
10.1200/jco.2013.31.15_suppl.tps1136
Abstract #
TPS1136
Poster Bd #
33C
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase I/II trial evaluating the safety and efficacy of eribulin in combination with copanlisib in patients with metastatic triple-negative breast cancer (TNBC).
First Author: Nusayba Ali Bagegni
Poster
2020 ASCO Virtual Scientific Program
Circulating tumor DNA (ctDNA) to evaluate stage III and stage IV metastatic breast cancer (MBC), describe tumor heterogeneity, and outcome.
First Author: Qiang Zhang
Poster
2020 ASCO Virtual Scientific Program
Patient-matched tissue and liquid biopsies identify shared and acquired genomic alterations in breast cancer.
First Author: Ethan Sokol
Poster
2017 ASCO Annual Meeting
Genomic profiling of circulating tumor DNA (ctDNA) from patients (pts) with metastatic breast cancer (mBC).
First Author: Lajos Pusztai